Document Detail


Anti-tumour activity of fotemustine and protons in combination with bevacizumab.
MedLine Citation:
PMID:  20551638     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Metastatic melanoma is one of the most aggressive tumours and is also very resistant to current therapeutic approaches. The aim of this investigation was the in vitro study of the anti-proliferative effects of fotemustine (FM; 100 and 250 microM), bevacizumab (5 microg/ml) and proton irradiation (12 and 16 Gy) on resistant HTB140 human melanoma cells.
METHODS: Viability was estimated by sulphorhodamine B assay, while cell proliferation was analyzed by 5-bromo-2-deoxyuridine assay. Cell cycle distribution and apoptosis were examined using flow cytometry.
RESULTS: Cell viability and proliferation were reduced after all applied treatments. The level of apoptosis significantly increased after treatment with FM, protons or a combination of all agents, while the apoptotic index ranged from 1.2 to 9.2. Proton irradiation, as well as combined treatment with bevacizumab and protons or 100 microM FM, bevacizumab and protons, have reduced melanoma cell proliferation through the induction of G1 phase arrest. Single FM (250 microM) or bevacizumab treatment and their combination, as well as the joint application of these 2 agents with protons, reduced cell proliferation and provoked G2 phase accumulation.
CONCLUSION: The analyzed treatments reduced cell viability and proliferation, triggered G1 or G2 cell cycle phase accumulation and stimulated apoptotic cell death.
Authors:
Lela B Korićanac; Jelena J Zakula; Ivan M Petrović; Lucia M Valastro; Giuseppe A P Cirrone; Giacomo Cuttone; Aleksandra M Ristić-Fira
Related Documents :
6195168 - Butyrate inhibits mouse fibroblasts at a control point in the g1 phase.
12829748 - Dynamic behavior of nuf2-hec1 complex that localizes to the centrosome and centromere a...
3427608 - Cell cycle related [3h]thymidine uptake and its significance for the incorporation into...
6641718 - Cell cycle regulation of histone h1o in cho cells: a flow cytofluorimetric study after ...
9764538 - Dual expression of gaba or serotonin and dopamine in xenopus amacrine cells is transien...
9571198 - Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial c...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-11
Journal Detail:
Title:  Chemotherapy     Volume:  56     ISSN:  1421-9794     ISO Abbreviation:  Chemotherapy     Publication Date:  2010  
Date Detail:
Created Date:  2010-06-30     Completed Date:  2011-03-08     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  214-22     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Apoptosis / drug effects,  physiology
Cell Line, Tumor
Cell Survival / drug effects,  physiology
Humans
Nitrosourea Compounds / administration & dosage*
Organophosphorus Compounds / administration & dosage*
Protons*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Nitrosourea Compounds; 0/Organophosphorus Compounds; 0/Protons; 2S9ZZM9Q9V/bevacizumab; 92118-27-9/fotemustine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croati...
Next Document:  Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts...